Results: During the study period, a total of 173,628 deliveries met the inclusion criteria; 1605 (0.9%) occurred in patients with “”isolated”" obesity. Higher rates of CD were found among patients with “”isolated”" obesity (30.7% vs. 12.3%; odds ration [OR] = 3.2; p < 0.001). When controlling for possible confounders, using a multivariable model with CD as the outcome variable, Poziotinib ic50 the association between “”isolated”" obesity and CD remained significant (adjusted OR = 2.6; p < 0.001). No significant differences were found in the risks of perinatal complications including perinatal mortality, shoulder dystocia, congenital malformations, and low 5-min Apgar score.

Conclusion: “”Isolated”" obesity, although not a risk factor for adverse perinatal outcomes, is an independent risk factor for CD.”
“Stents are structural implants with widespread clinical use in vascular

intervention to re-open stenotic vessels for the treatment of coronary artery disease and peripheral arterial occlusive disease. Apart from their mechanical function, current drug-eluting stents (DES) utilize local drug delivery selleck inhibitor from a drug-incorporated permanent polymer coating to prevent in-stent restenosis. This delayed closure of the stented vessel is considered one of the major limitations of conventional bare metal stents (BMS). The long-term safety of DES, however, is still under debate, with reported cases of delayed healing, late thrombosis and hypersensitivity demanding further evolution in this field. A promising approach to circumvent the limitations of first generation DES is the application of degradable polymer coatings in second generation DES, and fully absorbable polymer stents. From a materials and engineering perspective, this paper provides a mini-review of current clinically relevant DES technology A-1210477 and recent advancements in the development of stents from degradable polymeric materials as an alternative to permanent BMS and DES. This review, includes work on degradable stents and coatings based on blends of polylactic acid and the microbially-produced poly(4-hydroxybutyrate). (C) 2009 Society of Chemical Industry”
“Objective: To determine

whether an abnormal 50-g glucose-challenge test (GCT) is independently associated with adverse pregnancy outcome. Methods: A retrospective study of women with abnormal GCT (>140 mg/dL) but normal subsequent 100-g oral glucose-tolerance test (OGTT). Pregnancy outcome was compared with that of women with normal GCT (<140 mg/dL). Results: Of the 79,153 women delivered during the study period, the results of the GCT were available for 14,268. Of these, 809 (5.7%) had an abnormal GCT and normal OGTT and were eligible for the study group. An abnormal GCT was independently associated with an increased risk for macrosomia (odds ratio [OR] = 2.0, 95% CI: 1.5-2.7), large for gestational age (OR = 1.6, 95% CI: 1.3-2.0), cesarean section (OR = 1.3, 95% CI: 1.1-1.6), respiratory morbidity (OR = 1.6, 95% CI: 1.1-2.